Loading…

Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer

With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external be...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2014, Vol.4, p.214-214
Main Authors: Vargo, John A, Ferris, Robert L, Clump, David A, Heron, Dwight E
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53
cites cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53
container_end_page 214
container_issue
container_start_page 214
container_title Frontiers in oncology
container_volume 4
creator Vargo, John A
Ferris, Robert L
Clump, David A
Heron, Dwight E
description With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer. Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R). Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains. Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.
doi_str_mv 10.3389/fonc.2014.00214
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f</doaj_id><sourcerecordid>1557082643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</originalsourceid><addsrcrecordid>eNpVkc9PHCEcxUnTphr17K3h2Muu_BxmLk0a01YTkx5qE2-EH19c7OwwBbZm__uy7mqUC_B4fODlIXROyZLzfrgIaXJLRqhYEsKoeIeOGeNiMQh-9_7V-gidlfJA2ugkoYR_REdMUqk4747R468KGVI1rkaHbfJbnI2Pqa4gm3mLTcFzjmuTt7hmMHUNU8UhZQyjhzxu8WxqbFrBj7Gu8Bp8dGZsepzS3BB2BLwC47GZPJ7A_cHOTA7yKfoQzFjg7DCfoN_fv91eXi1ufv64vvx6s3BcCbEAZ6HjVDHrh4GJtguOguotF9I6q7gMvBN-UEZ6RwXjzA_EBSqDBd-B5Cfoes_1yTzoQxSdTNRPQsr32uQWfQTtKQMFg6KKDg3pLJGMdD6QXlnPutBYX_aseWNbUNdiZzO-gb49meJK36d_WlDWM6oa4PMBkNPfDZSq17E4GEczQdoUTaVUpGed4M16sbe6nErJEF6eoUTv2te79vWuff3Ufrvx6fXvXvzPXfP_7ryvNA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1557082643</pqid></control><display><type>article</type><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><source>PubMed Central</source><creator>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</creator><creatorcontrib>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</creatorcontrib><description>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer. Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R). Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains. Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2014.00214</identifier><identifier>PMID: 25157336</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>cetuximab ; elderly ; head and neck cancer ; Oncology ; radiosurgery ; SBRT</subject><ispartof>Frontiers in oncology, 2014, Vol.4, p.214-214</ispartof><rights>Copyright © 2014 Vargo, Ferris, Clump and Heron. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</citedby><cites>FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128217/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128217/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,4021,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25157336$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vargo, John A</creatorcontrib><creatorcontrib>Ferris, Robert L</creatorcontrib><creatorcontrib>Clump, David A</creatorcontrib><creatorcontrib>Heron, Dwight E</creatorcontrib><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer. Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R). Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains. Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</description><subject>cetuximab</subject><subject>elderly</subject><subject>head and neck cancer</subject><subject>Oncology</subject><subject>radiosurgery</subject><subject>SBRT</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkc9PHCEcxUnTphr17K3h2Muu_BxmLk0a01YTkx5qE2-EH19c7OwwBbZm__uy7mqUC_B4fODlIXROyZLzfrgIaXJLRqhYEsKoeIeOGeNiMQh-9_7V-gidlfJA2ugkoYR_REdMUqk4747R468KGVI1rkaHbfJbnI2Pqa4gm3mLTcFzjmuTt7hmMHUNU8UhZQyjhzxu8WxqbFrBj7Gu8Bp8dGZsepzS3BB2BLwC47GZPJ7A_cHOTA7yKfoQzFjg7DCfoN_fv91eXi1ufv64vvx6s3BcCbEAZ6HjVDHrh4GJtguOguotF9I6q7gMvBN-UEZ6RwXjzA_EBSqDBd-B5Cfoes_1yTzoQxSdTNRPQsr32uQWfQTtKQMFg6KKDg3pLJGMdD6QXlnPutBYX_aseWNbUNdiZzO-gb49meJK36d_WlDWM6oa4PMBkNPfDZSq17E4GEczQdoUTaVUpGed4M16sbe6nErJEF6eoUTv2te79vWuff3Ufrvx6fXvXvzPXfP_7ryvNA</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Vargo, John A</creator><creator>Ferris, Robert L</creator><creator>Clump, David A</creator><creator>Heron, Dwight E</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2014</creationdate><title>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</title><author>Vargo, John A ; Ferris, Robert L ; Clump, David A ; Heron, Dwight E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>cetuximab</topic><topic>elderly</topic><topic>head and neck cancer</topic><topic>Oncology</topic><topic>radiosurgery</topic><topic>SBRT</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vargo, John A</creatorcontrib><creatorcontrib>Ferris, Robert L</creatorcontrib><creatorcontrib>Clump, David A</creatorcontrib><creatorcontrib>Heron, Dwight E</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vargo, John A</au><au>Ferris, Robert L</au><au>Clump, David A</au><au>Heron, Dwight E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2014</date><risdate>2014</risdate><volume>4</volume><spage>214</spage><epage>214</epage><pages>214-214</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>With a growing elderly population, elderly patients with head and neck cancers represent an increasing challenge with limited prospective data to guide management. The complex interplay between advanced age, associated co-morbidities, and conventional local therapies, such as surgery and external beam radiotherapy ± chemotherapy, can significantly impact elderly patients' quality of life (QoL). Stereotactic body radiotherapy (SBRT) is a well-established curative strategy for medical-inoperable early-stage lung cancers even in elderly populations; however, there is limited data examining SBRT as primary therapy in head and neck cancer. Twelve patients with medically inoperable head and neck cancer treated with SBRT ± cetuximab from 2002 to 2013 were retrospectively reviewed. SBRT consisted of primarily 44 Gy in five fractions delivered on alternating days over 1-2 weeks. Concurrent cetuximab was administered at a dose of 400 mg/m(2) on day -7 followed by 250 mg/m(2) on day 0 and +7 in n = 3 (25%). Patient-reported quality of life (PRQoL) was prospectively recorded using the previously validated University of Washington quality of life revised (UW-QoL-R). Median clinical follow-up was 6 months (range: 0.5-29 months). The 1-year actuarial local progression-free survival, distant progression-free survival, progression-free survival, and overall survival for definitively treated patients were 69, 100, 69, and 64%, respectively. One patient (8%) experienced acute grade 3 dysphagia and one patient (8%) experienced late grade 3 mucositis; there were no grade 4-5 toxicities. Prospective collection of PRQoL as assessed by UW-QoL-R was preserved across domains. Stereotactic body radiotherapy shows encouraging survival and relatively low toxicity in elderly patients with unresectable head and neck cancer, which may provide an aggressive potentially curative local therapy while maintaining QoL.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>25157336</pmid><doi>10.3389/fonc.2014.00214</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2014, Vol.4, p.214-214
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_d12e7e9717194d9cb05206df087bd26f
source PubMed Central
subjects cetuximab
elderly
head and neck cancer
Oncology
radiosurgery
SBRT
title Stereotactic body radiotherapy as primary treatment for elderly patients with medically inoperable head and neck cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A39%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stereotactic%20body%20radiotherapy%20as%20primary%20treatment%20for%20elderly%20patients%20with%20medically%20inoperable%20head%20and%20neck%20cancer&rft.jtitle=Frontiers%20in%20oncology&rft.au=Vargo,%20John%20A&rft.date=2014&rft.volume=4&rft.spage=214&rft.epage=214&rft.pages=214-214&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2014.00214&rft_dat=%3Cproquest_doaj_%3E1557082643%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3744-ecbe63172bd9924cbefc1e78b345bcb735f364d97a5dc14232d90cf15fbed6e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1557082643&rft_id=info:pmid/25157336&rfr_iscdi=true